Danaher stock sits in an unusual valuation spot right now, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a meaningful discount, while earnings-based multiples lean the other way and flag the shares as expensive.

• Over the past 5 years, Danaher shares have declined 18%, which means long-term holders have not yet seen a clear payoff from staying invested.
• Recent news around Leica Biosystems’ planned acquisition of StatLab and new Alzheimer’s testing capabilities at Beckman Coulter can support expectations for future cash flows, while an investigation into potential fiduciary duty breaches introduces governance risk that may weigh on how investors price the stock.
• Danaher currently screens as undervalued on 4 of 6 valuation checks, a mixed picture rather than a clear bargain or clear overvaluation, according to its value score of 4/6.

The issue now is whether Danaher’s 21.4% discount to its DCF-based intrinsic value estimate offers enough compensation, given that market multiples are already pricing the stock on the rich side.

Does Danaher Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model values Danaher by projecting future cash flows and discounting them back to today. In this view, Danaher is treated as a business with growing cash generation, not a short term trading idea.

Danaher’s latest twelve month free cash flow is about $5.1b, and the model assumes that cash flow continues to grow over time, reaching higher levels by the end of the next decade. On those assumptions, the DCF output points to an intrinsic value of about $261 per share, which sits roughly 21.4% above the current share price. The investigation into potential fiduciary duty breaches is one factor cited in explaining why the market is keeping a lid on the stock price even though the cash flow estimate is higher.

On the DCF numbers alone, Danaher stock currently appears undervalued relative to its projected cash generation.

Our Discounted Cash Flow (DCF) analysis suggests Danaher is undervalued by 21.4%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Is Danaher Getting Expensive on Earnings?

P/E is usually the cleanest shorthand for how much investors are willing to pay for Danaher’s earnings stream. Right now, Danaher trades on a P/E of about 39.5x, slightly below the Life Sciences industry average of roughly 41.0x and close to the peer average of 41.2x. The stock is therefore broadly in line with its sector on simple comparisons.

The fair P/E from the model, which seeks to match Danaher’s earnings profile, size and risk to a more tailored multiple, is lower at about 30.1x. That is a clear gap to the current 39.5x and implies the market is paying a premium relative to what this framework suggests as a more neutral valuation.

On the P/E numbers, Danaher stock currently appears overvalued compared with the multiple implied by its fundamentals in this model.

The Danaher Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this Danaher valuation puzzle leaves off by spelling out which assumptions about Danaher's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. Each narrative links a specific fair value estimate to a concrete story about Danaher's potential catalysts and risks, so you can monitor which version of events appears to be unfolding over time on the Community page.

Share a Narrative on Danaher to add your voice to the Simply Wall St community, set out a number driven view on how developments like Leica Biosystems’ planned StatLab acquisition or Beckman Coulter’s new Alzheimer’s testing capabilities could shape the story from here, and see how your thesis holds up as new results and news arrive.

Do you think there's more to the story for Danaher? Head over to our Community to see what others are saying!

The Bottom Line

For Danaher, the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside from here, while the earnings multiple view flags the stock as overvalued relative to a tailored fair P/E. That split comes down to what you trust more: the long term cash generation that the DCF is weighting heavily, or the premium multiple the market is already assigning based on growth expectations and sentiment. With broader valuation checks sending a mixed signal, the key question is whether Danaher’s cash flows and margins eventually grow into today’s rich multiple or whether the current discount to intrinsic value is simply compensation for governance and execution risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.